Evidence map›Paper›PMID 34643804›Full record

ArticleActa neurochirurgica2022

The utility of plasma circulating cell-free messenger RNA as a biomarker of glioma: a pilot study.

Michael Itak Ita, Jiang Huai Wang, André Toulouse, Chris Lim, Noel Fanning, Michael O'Sullivan, Yvonne Nolan, George Finbarr Kaar, Henry Paul Redmond

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta neurochirurgica, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.8field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Recent Developments in Blood Biomarkers in Neuro-oncology.Current neurology and neuroscience reports · 2023
    Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Michael Itak ItaDepartment of Neurological Surgery, Cork University Hospital, Wilton, Cork, Ireland. 118227173@umail.ucc.ie.ORCID http://orcid.org/0000-0002-8187-5997
Jiang Huai WangDepartment of Academic Surgery, University College Cork, Cork, Ireland.
André ToulouseDepartment of Anatomy and Neuroscience, University College Cork, Cork, Ireland.
Chris LimDepartment of Neurological Surgery, Cork University Hospital, Wilton, Cork, Ireland.
Noel FanningDepartment of Neuroradiology, University College Cork, Cork, Ireland.
Michael O'SullivanDepartment of Neurological Surgery, Cork University Hospital, Wilton, Cork, Ireland.
Yvonne NolanDepartment of Anatomy and Neuroscience, University College Cork, Cork, Ireland.
George Finbarr KaarDepartment of Neurological Surgery, Cork University Hospital, Wilton, Cork, Ireland.
Henry Paul RedmondDepartment of Academic Surgery, University College Cork, Cork, Ireland.
University College Cork · IECork University Hospital · IE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundResearch into the potential utility of plasma-derived circulating cell-free nucleic acids as non-invasive adjuncts to radiological imaging have been occasioned by the invasive nature of brain tumour biopsy. The objective of this study was to determine whether significant differences exist in the plasma transcriptomic profile of glioma patients relative to differences in their tumour characteristics, and also whether any observed differences were representative of synchronously obtained glioma samples and TCGA glioma-derived RNA.

methodsBlood samples were collected from twenty glioma patients prior to tumour resection. Plasma ccfmRNAs and glioma-derived RNA were extracted and profiled.

resultsBCL2L1, GZMB, HLA-A, IRF1, MYD88, TLR2, and TP53 genes were significantly over-expressed in glioma patients (p < 0.001, versus control). GZMB and HLA-A genes were significantly over-expressed in high-grade glioma patients (p < 0.001, versus low-grade glioma patients). Moreover, the fold change of the BCL2L1 gene was observed to be higher in patients with high-grade glioma (p = 0.022, versus low-grade glioma patients). There was positive correlation between the magnitude of fold change of differentially expressed genes in plasma- and glioma-derived RNA (Spearman r = 0.6344, n = 14, p = 0.017), and with the mean FPKM in TCGA glioma-derived RNA samples (Spearman r = 0.4614, n = 19, p < 0.05). There was positive correlation between glioma radiographic tumour burden and the magnitude of fold change of the CSF3 gene (r = 0.9813, n = 20, p < 0.001).

conclusionWe identified significant differential expression of genes involved in cancer inflammation and immunity crosstalk among patients with different glioma grades, and there was positive correlation between their transcriptomic profile in plasma and tumour samples, and with TCGA glioma-derived RNA.

Indexed as

Brain NeoplasmsCell-Free Nucleic AcidsGliomaBiomarkersHLA-A AntigensHumansPilot ProjectsRNARNA, MessengerBiomarkersCell-Free Nucleic AcidsHLA-A AntigensRNARNA, MessengerBiomarkerCirculating cell-free messenger RNAGlioma

Identifiers

PMID34643804
PMCPMC8913523
OpenAlexW3207448822

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.